Profund Advisors LLC Sells 5,748 Shares of Eli Lilly And Co (NYSE:LLY)
Profund Advisors LLC cut its position in Eli Lilly And Co (NYSE:LLY) by 15.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,879 shares of the company’s stock after selling 5,748 shares during the quarter. Profund Advisors LLC’s holdings in Eli Lilly And Co were worth $3,532,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in Eli Lilly And Co by 1.7% in the 1st quarter. FMR LLC now owns 13,916,001 shares of the company’s stock valued at $1,805,741,000 after purchasing an additional 228,920 shares during the period. Northern Trust Corp lifted its position in shares of Eli Lilly And Co by 0.3% during the 2nd quarter. Northern Trust Corp now owns 11,056,098 shares of the company’s stock valued at $1,224,906,000 after acquiring an additional 32,421 shares during the period. Fisher Asset Management LLC lifted its position in shares of Eli Lilly And Co by 4.9% during the 2nd quarter. Fisher Asset Management LLC now owns 4,127,933 shares of the company’s stock worth $457,334,000 after buying an additional 192,702 shares during the last quarter. California Public Employees Retirement System lifted its position in shares of Eli Lilly And Co by 8.1% during the 1st quarter. California Public Employees Retirement System now owns 3,162,898 shares of the company’s stock worth $410,418,000 after buying an additional 238,198 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in shares of Eli Lilly And Co by 5.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 3,080,350 shares of the company’s stock worth $399,706,000 after buying an additional 156,321 shares during the last quarter. Institutional investors and hedge funds own 76.78% of the company’s stock.
Several brokerages recently weighed in on LLY. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Goldman Sachs Group began coverage on Eli Lilly And Co in a research report on Tuesday, May 28th. They set a “buy” rating and a $135.00 price objective for the company. Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Finally, Bank of America set a $120.00 price objective on Eli Lilly And Co and gave the stock a “neutral” rating in a research report on Tuesday. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $122.93.
Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The business had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the firm earned $1.48 EPS. The business’s revenue for the quarter was up .9% compared to the same quarter last year. Sell-side analysts anticipate that Eli Lilly And Co will post 5.73 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were issued a $0.645 dividend. The ex-dividend date was Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.32%. Eli Lilly And Co’s payout ratio is presently 46.49%.
In other news, SVP Stephen F. Fry sold 9,452 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $115.00, for a total value of $1,086,980.00. Following the completion of the sale, the senior vice president now owns 100,211 shares of the company’s stock, valued at $11,524,265. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the completion of the sale, the senior vice president now directly owns 38,306 shares of the company’s stock, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: What is a portfolio manager?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.